## **AMENDMENT TO THE CLAIMS**

- 1. (Currently Amended) A method of treatment or prevention of a respiratory coronavirus infection in a patient comprising administering to said patient an effective amount of an alpha thymosin peptide selected from the group consisting of naturally occurring thymosin alpha 1 (TA1), synthetic TA1 having substantially the same sequence as naturally occurring TA1 and recombinant TA1 having substantially the same sequence as naturally occurring TA1.
- 2. (Canceled)
- 3. (Original) The method of claim 1 wherein said respiratory viral infection is SARS.
- 4. (Original) The method of claim 1 wherein said amount of alpha thymosin peptide is within a range of about 0.1-20mg.
- 5. (Original) The method of claim 4 wherein said range is about 0.5-10mg.
- 6. (Original) The method of claim 4 wherein said range is about 1-5mg.
- 7. (Original) The method of claim 1 wherein said alpha thymosin peptide is thymosin alpha 1.
- 8. (Original) The method of claim 7 wherein said thymosin alpha 1 is administered to said patient at a dosage within a range of about 1-5mg.
- 9. (Original) The method of claim 8 wherein said dosage is about 1.6-3.2mg.

Serial No. 10/553,317 Response to Office Action of 12/28/07 Page 3

- 10. (Original) The method of claim 1, further comprising administering to said patient an effective amount of an interferon.
- 11. (Original) The method of claim 10 wherein said interferon is interferon alpha.
- 12. (Original) The method of claim 11 wherein said amount of said interferon is about 1-3MU.
- 13. (Original) The method of claim 1 wherein said alpha thymosin peptide is conjugated to a polymer.
- 14. (Original) The method of claim 13 wherein said polymer is polyethylene glycol (PEG).
- 15. (Canceled).
- 16. (Original) The method of claim 15 wherein said PEG of said PEG-TA1 has a molecular weight of about 20,000.
- 17. (Original) The method of claim 1 wherein said alpha thymosin peptide is substantially continuously maintained in said patient in an immune stimulating-effective amount.
- 18. (Original) The method of claim 17 wherein said alpha thymosin peptide is administered by continuous infusion into said patient.
- 19. (Canceled).